Dipeptidyl-Peptidase IV Inhibitors

Known as: Dipeptidyl-Peptidase 4 Inhibitors, Inhibitors, Dipeptidyl-Peptidase IV, Dipeptidyl Peptidase 4 Inhibitors 
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN… (More)
National Institutes of Health

Related topics

Related topics

16 relations

Narrower (9)

ABT 341LinagliptinNN 7201alogliptin
(More)
Dipeptidyl Peptidase 4 Inhibitor [EPC]Dipeptidyl Peptidase 4 Inhibitors [MoA]Dipeptidyl Peptidase-4 InhibitorIn Blood
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors
To the Editor: The position statement of the American Diabetes Association (ADA) and the European Association for the Study of… (More)
Is this relevant?
Review
2010
Review
2010
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Type 2 diabetes (T2DM) is a complex disease combining defects in insulin secretion and insulin action. New compounds have been… (More)
Is this relevant?
2009
2009
Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.
The incidence of diabetes is increasing and affects 180 million adults worldwide, including 24 million in the United States, or 7… (More)
Is this relevant?
Review
2008
Review
2008
Dipeptidyl peptidase IV inhibitors and diabetes therapy.
Current type 2 diabetes therapies are mainly targeted at stimulating pancreatic beta-cell secretion and reducing insulin… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Incretin based therapies for type 2 diabetes mellitus.
The incretin effect denominates the phenomenon that oral glucose elicits a higher insulin response than intravenous glucose… (More)
Is this relevant?
Review
2006
Review
2006
Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
Glucagon-like peptide-1 is an insulinotropic hormone with antidiabetic potential due to its spectrum of effects, which include… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form.
BACKGROUND Analysis of plasma B-type natriuretic peptide (BNP) has suggested the in vivo formation of a truncated form, BNP (3-32… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
Review
2005
Review
2005
Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors.
The sole application of an inhibitor of the dipeptidyl peptidase DP IV (also DP 4, CD26, DPP-IV or DPP-4) to a mammal… (More)
Is this relevant?
Review
2003
Review
2003
Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Dipeptidyl-peptidase IV/CD26 (DPP IV) is a cell-surface protease belonging to the prolyloligopeptidase family. It selectively… (More)
Is this relevant?
Review
1998
Review
1998
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
The insulinotropic hormone, glucagon-like peptide 1 (GLP-1), which has been proposed as a new treatment for type 2 diabetes, is… (More)
Is this relevant?